Blue decoration ASCITrials.com logo

References

  1. NCI National Cancer Institute website. Available at: http://www.cancer.gov
  2. Cancer Network website. Available at: http://www.cancernetwork.com
  3. American Cancer Society website. Available at: http://www.cancer.org
  4. Brichard VG, Lejeune D. GSK’s Antigen-Specific Cancer Immunotherapy Programme: Pilot results leading to Phase III clinical development. Vaccine. 2007 25(Suppl 2):B61-71.
  5. Mitchell M. Cancer vaccines, a critical review - Part I. Current Opinion in Investigational Drugs. 2002 3(1):140-9.
  6. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Current Opinion in Immunology. 1997; 9:684-93.
  7. Vansteenkiste, J, Zielinski, M, Linder, A. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC). 43rd ASCO Annual Meeting Chicago USA 1-5 June 2007.
  8. WHO Fact Sheet No. 297 2006 Available at: http://www.who.int/mediacentre/factsheets/fs297/en/
  9. Parkin DM D.M. Parkin The Lancet Oncology 2: 533-543 (2001)